Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease.
Yanai H, Adachi H, Hakoshima M, Katsuyama H.
Int J Mol Sci. 2021 Aug 26;22(17):9221. doi: 10.3390/ijms22179221.
Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease.
Waheed Y, Yang F, Sun D.
Korean J Intern Med. 2021 Nov;36(6):1281-1293. doi: 10.3904/kjim.2020.340. Epub 2021 Jul 8.
Hyperuricemia and Cardiovascular Disease.
Zhang S, Wang Y, Cheng J, Huangfu N, Zhao R, Xu Z, Zhang F, Zheng W, Zhang D.
Curr Pharm Des. 2019;25(6):700-709. doi: 10.2174/1381612825666190408122557.
Uric Acid and Oxidative Stress-Relationship with Cardiovascular, Metabolic, and Renal Impairment.
Gherghina ME, Peride I, Tiglis M, Neagu TP, Niculae A, Checherita IA.
Int J Mol Sci. 2022 Mar 16;23(6):3188. doi: 10.3390/ijms23063188.
Management of Gout and Hyperuricemia in CKD.
Vargas-Santos AB, Neogi T.
Am J Kidney Dis. 2017 Sep;70(3):422-439. doi: 10.1053/j.ajkd.2017.01.055. Epub 2017 Apr 26.
Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.
Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Sanchez Lozada LG, Stahl E, Weiner DE, Chertow GM.
Am J Kidney Dis. 2018 Jun;71(6):851-865. doi: 10.1053/j.ajkd.2017.12.009. Epub 2018 Feb 27.
Hyperuricemia, the heart, and the kidneys - to treat or not to treat?
Petreski T, Ekart R, Hojs R, Bevc S.
Ren Fail. 2020 Nov;42(1):978-986. doi: 10.1080/0886022X.2020.1822185.
Research Advances in the Mechanisms of Hyperuricemia-Induced Renal Injury.
Su HY, Yang C, Liang D, Liu HF.
Biomed Res Int. 2020 Jun 26;2020:5817348. doi: 10.1155/2020/5817348. eCollection 2020.
Hyperuricemia: An Intriguing Connection to Metabolic Syndrome, Diabetes, Kidney Disease, and Hypertension.
Vareldzis R, Perez A, Reisin E.
Curr Hypertens Rep. 2024 Jun;26(6):237-245. doi: 10.1007/s11906-024-01295-3. Epub 2024 Jan 25.
The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy.
Hu H, Li W, Hao Y, Peng Z, Zou Z, Wei J, Zhou Y, Liang W, Cao Y.
Cell Rep Med. 2024 Aug 20;5(8):101690. doi: 10.1016/j.xcrm.2024.101690.
